Allegro Ophthalmics Appoints Marc Carlson and Rebecca Colbert to the Company’s Board of Directors

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced that two new independent membersMarc Carlson and Rebecca Colberthave been appointed to the Companys Board of Directors with Ms. Colbert serving as Chairperson of the Boards Audit Committee. Bringing extensive executive level commercial and financial leadership experience from both private and public companies, Mr. Carlson and Ms. Colbert will help lead the companys strategy and direction as it expands its anti-integrin portfolio into new ocular therapeutic areas.

We are thrilled to welcome Marc and Rebecca to Allegros Board. They bring a tremendous amount of strategic leadership experience across a variety of industries at both large and small companies. Marc and Rebecca join an already stellar board that also includes Bill Link and Ron Kurtz, who are among the worlds most influential ophthalmic innovators. Together, their diverse expertise will serve our company extremely well as we continue to advance our current retina programs as well as clinical programs in new ocular therapeutic areas, said Vicken Karageozian, M.D., President & CEO, Allegro Ophthalmics.

Mr. Carlson brings more than 35 years of experience commercializing products in a variety of industries and creating value for shareholders. Formerly chief customer officer of DocuSign, Mr. Carlsons expertise helped DocuSign navigate a crowded marketplace and emerge as a leader in its space. His relentless focus on providing measurable value to customers and shareholders alike as well as his ability to develop creative growth stories and global brands were instrumental in the commercial growth of DocuSign from a $50 million private company to a public company with a nearly $10 billion market capitalization over a period of seven years.

As someone who has personally seen the impact of Luminate with my own eyes, I am excited to help Allegro build a global ophthalmic company that brings to market innovative products that make marked improvements in patients visual function, said Mr. Carlson.

Currently chief financial officer at Vertos Medical, Inc., Ms. Colbert has more than 15 years of experience working in senior level positions for medical device companies, including in her role as vice president, customer and sales operations, U.S. Surgical at Bausch + Lomb before joining Vertos. As vice president of finance at eyeonics, Inc., Ms. Colbert played a significant role in the companys filing for its initial public offering and ultimate sale to Bausch + Lomb. She began her career at Deloitte as a certified public accountant.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

I am very pleased to join Allegros board at this critical time of growth and development, said Ms. Colbert. The mounting evidence behind the current portfolio is compelling, and I am enthusiastic about the potential for expansion beyond current applications. Allegro has assembled an impressive team consisting of management, board members and esteemed ophthalmic opinion leaders, and I look forward to working with them to achieve the companys objectives.

About Allegro Ophthalmics, LLC

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate), Allegros lead investigational anti-integrin compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as diabetic macular edema (DME) and intermediate dry age-related macular degeneration (intermediate dry AMD). Risuteganib successfully completed two Phase 2 DME studies and is currently being evaluated in a US Phase 2 intermediate dry AMD study. Allegro is preparing to expand its anti-integrin portfolio into new ocular therapeutic areas. For more information, visit www.allegroeye.com.

Luminate is a registered trademark of Allegro Ophthalmics, LLC.

MEDIA:
Michele Gray
Gray Communications, LLC
(917)
449-9250
[email protected]